Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

RAS wild-type

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

3845; 4893; 3265

Related biomarkers:

‹

›

RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) anlotinib Sensitive : C3 ASCO-GI 2023 - 2wk	anlotinib Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks anlotinib Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2wk	cetuximab + tislelizumab Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks cetuximab + tislelizumab Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	panitumumab Sensitive: A1 - Approval panitumumab Sensitive : A1	panitumumab Sensitive: A1 - Approval panitumumab Sensitive : A1
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	fruquintinib Sensitive: B - Late Trials fruquintinib Sensitive : B	fruquintinib Sensitive: B - Late Trials fruquintinib Sensitive : B
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B	bevacizumab Sensitive: B - Late Trials bevacizumab Sensitive : B
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2	ramucirumab Sensitive: C2 – Inclusion Criteria ramucirumab Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria bevacizumab + cetuximab Sensitive : C2	bevacizumab + cetuximab Sensitive: C2 – Inclusion Criteria bevacizumab + cetuximab Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria cetuximab + avelumab Sensitive : C2	cetuximab + avelumab Sensitive: C2 – Inclusion Criteria cetuximab + avelumab Sensitive : C2
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3	EGFR inhibitor Sensitive: C3 – Early Trials EGFR inhibitor Sensitive : C3
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	avelumab Sensitive: C3 – Early Trials avelumab Sensitive : C3	avelumab Sensitive: C3 – Early Trials avelumab Sensitive : C3
RAS wild-type	Colon Cancer	RAS wild-type	Colon Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	EGFR inhibitor + VEGF inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + VEGF inhibitor Sensitive : C3	EGFR inhibitor + VEGF inhibitor Sensitive: C3 – Early Trials EGFR inhibitor + VEGF inhibitor Sensitive : C3
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	panitumumab + cabozantinib tablet Sensitive: C3 – Early Trials panitumumab + cabozantinib tablet Sensitive : C3	panitumumab + cabozantinib tablet Sensitive: C3 – Early Trials panitumumab + cabozantinib tablet Sensitive : C3